| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-02-21 | Cytos Biotechnology (Switzerland) | EU consortium Grant | European Commission | |||
| 2011-02-17 | Orphazyme (Denmark) | €3 million | extension of a seed financing round | Sunstone Capital (Denmark) - Novo A/S (Denmark) | Rare diseases | Fundraising |
| 2011-02-15 | Newron Pharmaceuticals (Italy) | €3.7 million | grant | Ministero dell’ Istruzione, dell’ Università e della Ricerca (Italy) | CNS diseases - Neurodegenerative diseases | Grant |
| 2011-02-11 | Biotec Pharmacon (Norway) | NOK 7.56 million | private placement | Private placement | ||
| 2011-02-07 | Galapagos (Belgium) | €2.7 million | grant | Flemish agency for Innovation by Science and Technology (IWT) (Belgium) | Infectious diseases | Grant |
| 2011-02-03 | AB Science (France) | €1.7 million | credit line | BNP Paribas (France) ABN AMRO (The Netherlands) | Cancer - Oncology | Fundraising |
| 2011-02-03 | Digna Biotech (Spain), Centro de Investigación Médica Aplicada (CIMA) de la Universidad de Navarra (Spain) | € 1.3 million | grant | European Union | Rare diseases | Grant |
| 2011-02-03 | to-BBB (The Netherlands) | €4 million | Series B investment round | Jonghoud International BV (The Netherlands) - Industrial Bank of Taiwan Management Corporation (IBTM) (Taiwan) - Aescap Venture (The Netherlands) - Antea Participaties (The Netherlands) | Cancer - Oncology | Fundraising |
| 2011-02-02 | Scil Proteins (Germany) | €24 million | financing round | BioNet Holding | Cancer - Oncology | Fundraising |
| 2011-02-01 | Mologen (Germany) | €10 million | private placement | Cancer - Oncology - Infectious diseases | Private placement | |
| 2011-02-01 | ActoGeniX (Belgium) | €0.53 million | grant | Flemish agency for Innovation by Science and Technology (IWT) (Belgium) | Infectious diseases | Grant |
| 2011-01-31 | Amsterdam Molecular Therapeutics (The Netherlands) | € 1.1 Million | EU consortium Grant | AIPGENE consortium The AIPGENE consortium is led by Fundación para la Investigatión Médica Aplicada (FIMA, Spain), and in addition to AMT, includes Clínica Universidad de Navarra (Spain), Stockholms Läns Landsting (Sweden), Deutsches Krebsforschungszentrum (Germany), Digna Biotech (Spain) and Servicio Madrileño de Salud (Spain). | Rare diseases - Genetic diseases | Grant |
| 2011-01-27 | Active Biotech (Sweden) | SEK 375 million before transaction costs.(€ 42,595 million) | private placement of 2,500,000 new shares | Autoimmune diseases - Cancer - Oncology | Private placement | |
| 2011-01-26 | Microvisk Technologies (UK) | £6 million (€ 7.02 million ) | rights issue to existing investors | Porton Capital, Oxford Technology Management, New Hill ( Boston , USA ), Midven, the Rainbow Seed Fund, Finance Wales and private investors. | Cardiovascular diseases -Hematological diseases | Fundraising |
| 2011-01-21 | InDex Pharmaceuticals (Sweden) | SEK 75 million (€8.35 million) | financing round | Industrifonden (Sweden) - current investors - SEB Venture Capital | Autoimmune diseases – Inflammatory diseases | Fundraising |
| 2011-01-20 | Genfit (France) | € 4.9 million | ISI grant | OSEO (France) | Cardiovascular diseases - Metabolic diseases - Liver diseases | Grant |
| 2011-01-18 | Diagnoplex (Switzerland) | CHF 10 million (€7.7 million) | series A financing round | Debiopharm Group (Switzerland) Novartis Venture Fund (Switzerland) NeoMed (Switzerland) Initiative Capital Romandie (Switzerland) |
Cancer - Oncology | Fundraising |
| 2011-01-13 | Complix (Belgium) | €2 million | series A financing round | Credit Agricole Private Equity (France) | Autoimmune diseases - Infectious diseases | Fundraising |
| 2011-01-12 | Vaximm (Switzerland - Germany) | CHF 7.8 million (€.14 million) | financing round | BB Biotech Ventures (UK) - Merck KGaA (Germany) - Sunstone Capital (Denmark) - Merck Serono Ventures (Germany - Switzerland) - BioMedPartners (Switzerland) | Cancer - Oncology | Fundraising |
| 2011-01-12 | Celyad previously known as Cardio3 Biosciences (Belgium) | €3.1 million | cash advance, grant | Walloon Region (Belgium) - European Commission’s Seventh Framework Program (FP7) | Cardiovascular diseases | Grant |
